Morning Watchlist: Wednesday Edition
A quick note from Behind the Markets
We're at the middle of the week, and the market comes into it warm. On Monday the Nasdaq jumped 2.3% — its best day since early August — as oil slid toward $98 and the front page traded central bankers for diplomats.
But the rally isn't this morning's story. Today, an FDA advisory panel sits down to vote on whether a single tube of blood can screen for dozens of cancers at once. On Monday, the company behind that test jumped 36% before the panel said a word.
That's one of three crowds we're stepping behind this morning. Three stories. Three pairings. Let's get into it.
1) The Blood Test Goes to Washington
Grail's Galleri test looks for cancer's chemical fingerprints on DNA fragments floating in the bloodstream — one draw, dozens of cancer types, most of them cancers nobody screens for today. On Monday, the FDA posted its staff briefing documents ahead of today's advisory committee vote, and the language was unusually warm: the test "substantially increased cancer detection" with "a very low false-positive rate."
Grail stock rose 36.6% to $110.30 in a day. The prize is real: an FDA approval is the likeliest road to Medicare and insurance reimbursement — the difference between a boutique test people pay for out of pocket and screening at population scale.
But look at what you'd be buying after Monday. Grail earned $44.7 million of revenue last quarter and lost $2.56 a share. Chasing a 36% pop into a binary vote is not our sport. So step back and ask the quieter question: if blood-based cancer screening becomes real medicine — Grail's version, or any of its rivals' — what does every one of those millions of tests need?
A sequencing machine to read it.
The pairing: Illumina (ILMN) — Watch
Illumina sells the printing presses of genomic medicine; Grail — which was actually born inside Illumina before regulators forced them apart in 2024 — prints one newspaper. Whoever's cancer test wins, the DNA gets read, and Illumina makes the readers. The company even took The Trade Desk's vacated S&P 500 seat on Monday (we grade TTD below).
So why Watch and not Buy? The crowd found the printing press first. At $238.82, Illumina has nearly tripled off its 52-week low of $88, sits about 4% under its high, and costs roughly 42 times next year's expected earnings — the S&P 500 costs 21 — while revenue is growing about 5%. The average analyst target, $202.65, is now below the price: targets chasing price, the same warning we flagged on Tenable and Okta. Our entrance: an air pocket — a surprise "no" from today's panel would make one — or revenue reaccelerating enough to earn the multiple, starting with the October 29th report. The kill: clinical volumes stalling, or a deep-pocketed rival finally shipping a credible sequencer.
2) The Pioneer Guides to Average
On Monday in London, Novo Nordisk — the company that invented the obesity-drug era — held a capital markets day to explain what comes after it. The targets: more than $23 billion a year in obesity revenue by 2030, five-plus potential blockbusters to market, and enough oral GLP-1 capacity to serve roughly ten times more patients. New CEO Mike Doustdar was also plain about the calendar: U.S. exclusivity on semaglutide — the molecule behind Ozempic and Wegovy, more than half of company sales — runs out in 2032.
The market heard one word: average. Guided growth in line with ordinary pharma peers, from the company that was briefly Europe's most valuable. The stock fell about 7%. Eli Lilly barely moved.
Here's what we keep coming back to. A patent cliff doesn't shrink this market — it multiplies the players in it. Brands, rivals, and eventually copycats, all making more drug in more formats for more patients.
The pairing: Stevanato Group (STVN) — Watch
Stevanato is the bottle maker in the cola wars. The Italian company — founded 1949, still family-controlled — makes the glass vials, cartridges, prefilled syringes and pen injectors that injectable drugs ship in, whoever's name is on the label. Its new Alina pen just picked up European marketing authorizations under GLP-1 combination products, and second-quarter revenue grew 8% to €302 million, with plants ramping in Latina, Italy and Fishers, Indiana to serve exactly this wave.
At $21.51 it's a $5.9 billion company. So why not Buy? Price, mostly: about 28 times next year's expected earnings for single-digit growth is a full tag against the S&P's 21. (The American peer, West Pharmaceutical, costs 43 times — the whole aisle is priced for the boom.) Our entrance: a pullback toward the high teens, or earnings reaccelerating as the new plants fill. The honest kill switch came from Novo's own stage on Monday: that tenfold oral capacity plan. Pills need no pens.
3) The Merger That Signed a Supply Contract
The last obstacle to the biggest media deal in a generation fell on Monday: Paramount Skydance settled with twelve state attorneys general (and the writers' union), clearing its $111 billion purchase of Warner Bros. Discovery. The FCC signed off on Friday. Warner stock rose 11% to $30.80, and the arbitrage crowd celebrated.
We read the settlement terms instead, and one number stopped us. To win the states over, the combined company must produce at least 30 films a year for two years, then 32 a year for three more — with financial penalties if it doesn't — plus an extra $300 million a year spent on domestic production, with the two studios run separately for now.
Mergers usually mean fewer movies; that was the whole fear. This one comes with a court-monitored production floor.
The pairing: Cinemark (CNK) — Buy
Cinemark runs roughly 500 theaters across the Americas, and it's the tavern on the corner while the breweries merge: it pours whichever studio's beer wins. Business was already strong before Monday's news — the summer quarter was the first in company history above $1 billion of revenue, with record adjusted EBITDA and more than 1.5 million paying Movie Club subscribers.
The stock rose 3.6% Monday to $36.25, and it still costs about 15 times next year's expected earnings. The S&P 500: 21 times. Eleven analysts rate it Buy with a $40 average target, and there's a small dividend while you wait. Honest flags: the stock is up 68% from its 52-week low, so we're not early; film slates are lumpy, and a reorganizing mega-studio could still leave gaps in 2027; and the settlement counts films produced, not necessarily films sent to theaters — if that floor gets satisfied with streaming releases, the tavern pours less than we expect. The squeezed consumer at record pump prices is the macro risk it shares with half our ledger.
Before You Go
That's the watchlist: the machine that reads every cancer test, the bottle maker behind the obesity war, and the theater chain holding the merger's homework. One theme, as always: the best opportunities stand one step behind the headline.
Two grades we owed you. The Trade Desk's deletion day came and went — Monday's close was $13.88, down all of 0.3%, and the 52-week low was never touched. No washout printed, so no entrance; the forced sellers finished with a shrug, and the business still has to prove the ad dollars come back. Still Watch.
Tuesday morning AutoZone beat: earnings of $56.05 a share against roughly $54 expected, sales up 5.6%, domestic comparable sales up 1.6%, with tariff refunds fattening margins. The parts aisle graded fine, not great — Sunday's LKQ Buy is unchanged.
Also worth a line: oil's slide (WTI near $98) came on Saudi pipeline repairs and de-escalation hopes with Iran's president in New York — the "cheerful loss" scenario for our energy shelf stays live, and Copa remains its designated winner. Thursday is circled twice: Trump and Xi in Washington, and Costco after the closing bell, with our September 6th Sell-and-Buy pair listening.
Found this helpful? Share it with others.
Written by Behind the Markets